Dengue-specific subviral nanoparticles: design, creation and characterization.
Name:
Khetarpal et al_final.pdf
Size:
1.004Mb
Format:
PDF
Description:
Open Access publication
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Khetarpal, NiyatiPoddar, Ankur
Nemani, Satish K
Dhar, Nisha
Patil, Aravind
Negi, Priyanka
Perween, Ashiya
Viswanathan, Ramaswamy
Lünsdorf, Heinrich
Tyagi, Poornima
Raut, Rajendra
Arora, Upasana
Jain, Swatantra K
Rinas, Ursula
Swaminathan, Sathyamangalam
Khanna, Navin
Issue Date
2013
Metadata
Show full item recordAbstract
Dengue is today the most significant of arboviral diseases. Novel tools are necessary to effectively address the problem of dengue. Virus-like particles (VLP) offer a versatile nanoscale platform for developing tools with potential biomedical applications. From the perspective of a potentially useful dengue-specific tool, the dengue virus envelope protein domain III (EDIII), endowed with serotype-specificity, host receptor recognition and the capacity to elicit virus-neutralizing antibodies, is an attractive candidate.Citation
Dengue-specific subviral nanoparticles: design, creation and characterization. 2013, 11 (1):15 J NanobiotechnologyAffiliation
Recombinant Gene Products Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India. swami@icgeb.res.in.Journal
Journal of nanobiotechnologyPubMed ID
23706089Type
ArticleLanguage
enISSN
1477-3155ae974a485f413a2113503eed53cd6c53
10.1186/1477-3155-11-15
Scopus Count
The following license files are associated with this item:
Related articles
- Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
- Authors: Arora U, Tyagi P, Swaminathan S, Khanna N
- Issue date: 2013 Jan 30
- A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
- Authors: Ramasamy V, Arora U, Shukla R, Poddar A, Shanmugam RK, White LJ, Mattocks MM, Raut R, Perween A, Tyagi P, de Silva AM, Bhaumik SK, Kaja MK, Villinger F, Ahmed R, Johnston RE, Swaminathan S, Khanna N
- Issue date: 2018 Jan
- Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.
- Authors: Arora U, Tyagi P, Swaminathan S, Khanna N
- Issue date: 2012 Jul 13
- Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
- Authors: Poddar A, Ramasamy V, Shukla R, Rajpoot RK, Arora U, Jain SK, Swaminathan S, Khanna N
- Issue date: 2016 Jun 14
- Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
- Authors: Li XQ, Qiu LW, Chen Y, Wen K, Cai JP, Chen J, Pan YX, Li J, Hu DM, Huang YF, Liu LD, Ding XX, Guo YH, Che XY
- Issue date: 2013 Oct